Granja holdings Hengrui 40 million shares

On the evening of October 28, Hengrui Pharmaceutical released its third-quarter 2022 results report. Third quarter revenue of 5.717 billion yuan, down 17.16% year on year; Net profit attributable to shareholders of listed companies was 1.054 billion yuan, down 31.54% year-on-year.

Notably, revenue has started to grow again after three straight quarters of decline.

In July 2021, when the chairman of Hengrui medicine Zhou Yunshu suspected of insider trading, gone with the wind total re-emergence, so far more than 400 days. Gone with the wind always in charge of streamlining personnel, technology research and development, and now revenue growth.

On October 26, the fund managed by "medicine goddess Gulen" released its third quarterly report. Ceibs Healthcare holds 60,365,600 shares of Hengrui Pharmaceutical, an increase of 97.52% compared with the previous period, ranking eighth. Ceibs Medical Innovation holds 15.1743 million shares of Hengrui Medicine, an increase of 437.96% compared with the previous period, ranking ninth in the heavy stock. The two funds added to hold more than 40 million shares of Hengrui medicine.

Hengrui Pharmaceutical has the deepest R&D pipeline among the domestic innovative drug companies. The number of innovative drugs on the market has reached 11, and the number of innovative drugs in NDA stage has reached 6. There are 12 innovative drugs in phase III, including the HER2 ADC novel SHR-A1811, which is benchmarked to DS8201.

Third quarter results show that Hengrui momentum, revenue growth is back, is expected to get out of the mud, innovation driven second spring.